2 papers and 0 clinical trials exploring lsd as a treatment for borderline personality disorder (bpd).
LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.
Full LSD profileResearch into psychedelic-assisted therapies for Borderline Personality Disorder (BPD) indicates promising potential, particularly with compounds such as ketamine and MDMA, which may enhance emotional processing and neuroplasticity. However, systematic exclusion of BPD patients from psychedelic trials has limited available data, highlighting the need for dedicated research in this area.
Full Borderline Personality Disorder (BPD) profileNo clinical trials have been tagged with both LSD and Borderline Personality Disorder (BPD) yet.
Trials are continuously being added as new studies are registered.